Pharma and the USFDA
US drug approvals, inspections, pricing and patents — generic makers and contract manufacturers.
Stories, last 30 days
15
Stories, six months
21
Companies named
21
Sectors named
16
1
1
4
10
Stories on this theme, week by week
Latest stories
- Sensex ends 429 points lower at 72,639 after the RBI increase; the metal index drops 2.3%, PSU banks and media gain 7 Oct 2026
- CVC and GBL lift their bid for Italian drugmaker Recordati to €53 a share, call it final and extend the offer to October 23 6 Oct 2026 EU
- Sensex ends 685 points higher at 73,068 as Brent slips under $100 a day before the RBI rate decision 6 Oct 2026
- CD&R and McKesson agree to buy home-infusion provider Option Care Health for $32.05 a share, about $5.8 billion 6 Oct 2026 US
- China's DeepSeek is reported to target at least $12 billion in new funding at about a $74 billion valuation ahead of a 2027 IPO 6 Oct 2026 US
- Genmab jumps about 9% after its lymphoma drug with AbbVie halves the risk of progression in a Phase 3 trial 5 Oct 2026 EU US
- Two biotech IPOs open their books in the US: TRex Bio seeks $125 million and Retension Pharmaceuticals $40 million 5 Oct 2026 US
- STOXX 600 ends 0.4% higher but France's CAC 40 drops to a six-month low on budget worries 5 Oct 2026 EU
- IMF says India can let the rupee absorb the shock of US rate increases 4 Oct 2026
- Naukri index: AI/ML hiring up 20% in September while IT services hiring falls 4% 3 Oct 2026
- US trade chief says India deal is in the 'short strokes' but not imminent after a Modi-Trump call 2 Oct 2026
- Fresenius buys the remaining 45% of biosimilars maker mAbxience for up to €750 million 1 Oct 2026 EU
- US 100% tariff on patented drugs starts Sept 29; generics stay outside it and India gets zero duty on select specialty medicines 29 Sep 2026
- US tariffs of up to 100% on patented drug imports now cover every branded drugmaker as the final phase starts 29 Sep 2026 US
- White House extends most-favoured-nation drug prices to every state Medicaid programme, with 26 drugmakers signed up 18 Sep 2026 US
- Novo Nordisk lifts 2026 outlook to 0% to -6% for sales and profit as Wegovy pill prescriptions pass 265,000 a week 4 Aug 2026 EU
- India-UK free trade pact takes effect July 15, ending UK duties on textiles, seafood, leather and auto parts 13 Jul 2026
- EU reaches political deal to scrap tariffs on US industrial goods under the pact that set a 15% US tariff ceiling on EU cars 20 May 2026 EU
- Rupee slides to an all-time low of 96.96 per dollar, down over 6% since the Iran war began 20 May 2026
- Brent touches $126, a four-year high, as US-Iran talks stall; rupee slides to 95.34 and Sensex sheds 583 points 30 Apr 2026
Sectors these stories name
Healthcare (5 stories)
−0.6%
Chemicals (2 stories)
+0.6%
How often each sector is named in these stories, and the median 5-session move of its stocks. A record, not a forecast.
Companies these stories name
| Company | Stories | 5 sessions | 20 sessions |
|---|---|---|---|
| Adani Enterprises Ltd. ADANIENT | 2 | +4.01% | -7.64% |
| Kotak Mahindra Bank Ltd. KOTAKBANK | 2 | +2.98% | +7.55% |
| Sun Pharmaceutical Industries Ltd. SUNPHARMA | 2 | +0.24% | -5.53% |
| Adani Ports and Special Economic Zone Ltd. ADANIPORTS | 1 | +2.06% | +0.28% |
| Bharti Airtel Ltd. BHARTIARTL | 1 | +2.74% | +0.98% |
| Biocon Ltd. BIOCON | 1 | +0.57% | -7.37% |
| Cipla Ltd. CIPLA | 1 | +1.62% | -3.51% |
| Coal India Ltd. COALINDIA | 1 | +2.11% | 0.00% |
| Dr. Reddy's Laboratories Ltd. DRREDDY | 1 | +3.29% | +3.73% |
| HCL Technologies Ltd. HCLTECH | 1 | +15.56% | +8.08% |
| Hester Biosciences Limited HESTERBIO | 1 | +6.11% | -2.20% |
| Hindalco Industries Ltd. HINDALCO | 1 | +0.42% | -8.84% |
| ICICI Bank Ltd. ICICIBANK | 1 | +2.99% | +3.10% |
| Infosys Ltd. INFY | 1 | +11.33% | +4.86% |
| JSW Steel Ltd. JSWSTEEL | 1 | +2.14% | -4.23% |
| Reliance Industries Ltd. RELIANCE | 1 | +3.14% | -2.32% |
| Shilpa Medicare Ltd. SHILPAMED | 1 | -10.07% | -3.78% |
| Tech Mahindra Ltd. TECHM | 1 | +10.28% | +5.70% |
| Titan Company Ltd. TITAN | 1 | +2.21% | -7.96% |
| Trent Ltd. TRENT | 1 | +2.55% | +5.76% |
Ranked by how many of the stories name the company — a count, not a recommendation.